Literature DB >> 29322756

Canakinumab for Atherosclerotic Disease.

Alexander M Rothman1, Allison C Morton2, David C Crossman3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29322756     DOI： 10.1056/NEJMc1714635

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

Review 1.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

2.  Association between new circulating proinflammatory and anti-inflammatory adipocytokines with coronary artery disease.

Authors:  Tong Liu; Chao Han; Lixian Sun; Zhenjiang Ding; Fei Shi; Ruijuan Wang; Wenfeng Wang; Weichao Shan; Ying Zhang; Na Hu; Jingyi Liu; Haiwei Bu
Journal:  Coron Artery Dis       Date:  2019-11       Impact factor: 1.439

Review 3.  The Role of Tumor Necrosis Factor Associated Factors (TRAFs) in Vascular Inflammation and Atherosclerosis.

Authors:  Mark Colin Gissler; Peter Stachon; Dennis Wolf; Timoteo Marchini
Journal:  Front Cardiovasc Med       Date:  2022-02-17

4.  Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review.

Authors:  David Andaluz-Ojeda; Pablo Vidal-Cortes; Álvaro Aparisi Sanz; Borja Suberviola; Lorena Del Río Carbajo; Leonor Nogales Martín; Estefanía Prol Silva; Jorge Nieto Del Olmo; José Barberán; Ivan Cusacovich
Journal:  World J Crit Care Med       Date:  2022-07-09

5.  Dietary Docosahexaenoic Acid Reduces Oscillatory Wall Shear Stress, Atherosclerosis, and Hypertension, Most Likely Mediated via an IL-1-Mediated Mechanism.

Authors:  Mabruka A Alfaidi; Janet Chamberlain; Alexander Rothman; David Crossman; Maria-Cruz Villa-Uriol; Patrick Hadoke; Junxi Wu; Torsten Schenkel; Paul C Evans; Sheila E Francis
Journal:  J Am Heart Assoc       Date:  2018-06-30       Impact factor: 5.501

6.  Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS.

Authors:  Alexander Mk Rothman; Jean MacFadyen; Tom Thuren; Alastair Webb; David G Harrison; Tomasz J Guzik; Peter Libby; Robert J Glynn; Paul M Ridker
Journal:  Hypertension       Date:  2019-12-30       Impact factor: 10.190

Review 7.  Recent advances in antibody-based immunotherapy strategies for COVID-19.

Authors:  Abdolreza Esmaeilzadeh; Samaneh Rostami; Pegah M Yeganeh; Safa Tahmasebi; Majid Ahmadi
Journal:  J Cell Biochem       Date:  2021-06-23       Impact factor: 4.480
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.